1 research outputs found

    Synthesis of <sup>11</sup>C‑Labeled Thiamine and Fursultiamine for in Vivo Molecular Imaging of Vitamin B<sub>1</sub> and Its Prodrug Using Positron Emission Tomography

    No full text
    To enable in vivo analysis of the kinetics of vitamin B<sub>1</sub> (thiamine) and its derivatives by positron emission tomography (PET), <sup>11</sup>C-labeled thiamine ([<sup>11</sup>C]-<b>1</b>) has been synthesized. This was carried out via a rapid, multistep synthesis consisting of Pd<sup>0</sup>-mediated <i>C</i>-[<sup>11</sup>C]­methylation of a thiazole ring for 3 min and benzylation with 5-(bromomethyl)­pyrimidine for 7 min. The [<sup>11</sup>C]-<b>1</b> was also converted to <sup>11</sup>C-labeled fursultiamine ([<sup>11</sup>C]-<b>2</b>), a prodrug of vitamin B<sub>1</sub>, by disulfide formation with <i>S</i>-tetrahydrofurfurylthiosulfuric acid sodium salt. Characterization of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> showed them to be suitable for use as PET probes for in vivo pharmacokinetic and medical studies. The total durations of the preparations of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> were shorter than 60 and 70 min, respectively. The [<sup>11</sup>C]­CH<sub>3</sub>I-based decay-corrected radiochemical yields of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> were 9–16% and 4–10%, respectively. The radioactivities of the final injectable solutions of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> were 400–700 and 100–250 MBq, respectively. The radiochemical purity of both [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> was 99%, and the chemical purities of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> were 99% and 97–99%, respectively. In vivo PET imaging of normal rats was illustrated by the distribution of [<sup>11</sup>C]-<b>1</b> and [<sup>11</sup>C]-<b>2</b> following intravenous injection
    corecore